How often should I be screened after Lymphoma treatment

LymphomaMay 15, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Post-Treatment Lymphoma Screening: What You Should Know

This is an important question, and the answer depends on several factors specific to your situation. Let me explain the general approach, then highlight what you should discuss with your care team.

How Doctors Think About Post-Treatment Monitoring

After lymphoma treatment, your oncology team monitors you for two main reasons:

  1. To detect early signs of recurrence (cancer returning) before symptoms develop
  2. To manage side effects from treatment and watch for long-term health effects

The frequency and type of monitoring varies based on:

  • Your specific lymphoma type (follicular, DLBCL, marginal zone, etc.)
  • Your stage at diagnosis
  • How well you responded to treatment
  • Whether you achieved complete remission (no detectable cancer)
  • Your overall health and risk factors

General Monitoring Approach

According to NCCN Guidelines for Patients, most lymphoma survivors typically have:

  • More frequent visits early on (every 3 months for the first 1-2 years)
  • Gradually spaced visits as time passes without recurrence (every 6 months, then annually)
  • Imaging tests (CT scans or PET scans) at specific intervals determined by your doctor
  • Blood work to monitor blood counts and organ function
  • Physical exams to check for enlarged lymph nodes or other signs

Emerging Technology: Molecular Residual Disease (MRD) Testing

An important development is molecular residual disease (MRD) testing, which detects remaining cancer cells in your blood after treatment using circulating tumor DNA (ctDNA). According to recent NCCN Guidelines, MRD testing is now included in monitoring strategies for B-cell lymphomas like DLBCL and follicular lymphoma.

MRD testing can:

  • Detect recurrence approximately 200 days (6-7 months) earlier than standard imaging
  • Help guide how often you need imaging and follow-up visits
  • Identify patients who might benefit from additional treatment before symptoms appear

This technology is still being integrated into clinical practice, so ask your doctor if MRD testing is appropriate for your situation.

Questions to Ask Your Oncology Team

Since your specific screening schedule depends on your individual case, here are key questions:

  1. "Based on my lymphoma type and stage, what is my typical recurrence risk?"
  2. "How often should I have follow-up visits in the first year, second year, and beyond?"
  3. "What imaging tests do you recommend, and how frequently?"
  4. "Am I a candidate for MRD testing to guide my monitoring?"
  5. "What symptoms should I watch for between appointments and report immediately?"
  6. "Are there long-term side effects from my treatment I should monitor for?"

Important Context

The NCCN Guidelines for Patients emphasize that while regular monitoring is important, many lymphoma survivors live long, healthy lives after treatment. Your care team will personalize your follow-up plan based on your complete clinical picture—something no general guideline can do.


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: